Sunitinib malate for the treatment of pancreas malignancies – where does it fit?

Bibliography

• Mena AC, Pulido EG, Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010;21(Suppl 1):S3-11
   PubMed Web of Science ®Google Scholar
• Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002;62:2749-52
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
   PubMed Web of Science ®Google Scholar
• Breuss JM, Uhrin P. VEGF-initiated angiogenesis and the uPA/uPAR system. Cell Adh Migr 2012;6:6
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol 2011;55(3):261-8
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-40
   PubMed Web of Science ®Google Scholar
• Izzedine H, Buhaescu I, Rixe O, Deray G. Sunitinib malate. Cancer Chemother Pharmacol 2007;60(3):357-64
   PubMed Web of Science ®Google Scholar
• Klimstra DS, Modlin IR, Coppola D, The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39(6):707-12
   PubMed Web of Science ®Google Scholar
• Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of ki-67 immunostaining. Endocr Pathol 2008;19:282-8
   PubMed Web of Science ®Google Scholar
• Bosman F, Carneiro F, Hruban R, Theise N. editors. WHO Classification of tumours of the digestive system. IARC Press; Lyon, France; 2010: in press
   Google Scholar
• Hochwald SN, Zee S, Conlon KC, Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20:2633Y2642
   Web of Science ®Google Scholar
• Moran CA, Suster S, Coppola D, Neuroendocrine carcinomas of the lung: a critical analysis. Am J Clin Pathol 2009;131:206Y221
   Web of Science ®Google Scholar
• Moertel CG, Lefkopoulo M, Lipsitz S, Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326(8):519-23
   PubMed Web of Science ®Google Scholar
• La Rosa S, Sessa F, Capella C, Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996;429:323-33
   PubMed Web of Science ®Google Scholar
• Rindi G, Kloppel G, Couvelard A, TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-62
   PubMed Web of Science ®Google Scholar
• Rindi G, Kloppel G, Alhman H, TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395Y401
   Web of Science ®Google Scholar
• Jiao Y, Shi C, Edil BH, DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331(6021):1199-203
   PubMed Web of Science ®Google Scholar
• Moertel CG, Lavin PT, Hahn RG. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 1982;66(7):1567-9
   PubMedGoogle Scholar
• di Bartolomeo M, Bajetta E, Buzzoni R, Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors Cancer. 1996;77(2):402-8
   Google Scholar
• McCollum AD, Kulke MH, Ryan DP, Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004;27(5):485-8
   PubMed Web of Science ®Google Scholar
• Delaunoit T, Ducreux M, Boige V, The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 2004;40(4):515-20
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000;14(5):557-60
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M, Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21(14):2689-96
   PubMed Web of Science ®Google Scholar
• Ricci S, Antonuzzo A, Galli L, Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000;23(4):412-15
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose KJ, Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005;3:761-71
   PubMed Web of Science ®Google Scholar
• Fazio N, Spada F, Giovannini M. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. Cancer Treat Rev 2013;39(3):270-4
   PubMed Web of Science ®Google Scholar
• Cassier PA, Walter T, Eymard B, Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer 2009;115(15):3392-9
   PubMed Web of Science ®Google Scholar
• Olsen IH, Sørensen JB, Federspiel B, Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ScientificWorldJournal 2012;2012:170496
   PubMed Web of Science ®Google Scholar
• Chan JA, Stuart K, Earle CC, Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012;30(24):2963-8
   PubMed Web of Science ®Google Scholar
• Bono P, Rautiola J, Utriainen T, Joensuu H. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 2011;50(4):569-73
   PubMed Web of Science ®Google Scholar
• Cuneo KC, Geng L, Fu A, SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 2008;71(3):873-9
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-37.2003
   PubMed Web of Science ®Google Scholar
• Sun L, Liang C, Shirazian S, Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1Hpyrrole- 3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003 Mar 27;46(7):1116-19
   PubMed Web of Science ®Google Scholar
• Ding W, Cai T, Zhu H, Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo. Cancer Lett 2010;293(2):158-66
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
   PubMed Web of Science ®Google Scholar
• Welti JC, Powles T, Foo S, Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis 2012;15(4):623-41
   PubMed Web of Science ®Google Scholar
• Marzola P, Degrassi A, Calderan L, Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005;11(16):5827-32
   PubMed Web of Science ®Google Scholar
• Hanahan D. Heritable formation of pancreatic beta-cells: tumors in transgenic mice harboring recombinant insulin/simianvirus 40 oncogenes. Nature 1985;315(6015):115-22
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
   PubMed Web of Science ®Google Scholar
• Raymond E, Hammel P, Dreyer C, Sunitinib in pancreatic neuroendocrine tumors. Target Oncol 2012;7(2):117-25
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-95
   PubMed Web of Science ®Google Scholar
• Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 2010;28(29):4425-33
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K, Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;25-35
   PubMed Web of Science ®Google Scholar
• Kulke MH, Lenz HJ, Meropol NJ, Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26(20):3403-10
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Weber JM, Choi J, A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol 2012;23(9):2335-41
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A, Hoff PM, Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008;26(8):1316-23
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Fogleman D, Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediategrade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker [abstract 4002]. J Clin Oncol 2010;28(Suppl):15s
   PubMedGoogle Scholar
• Venook AP, Ko AH, Tempero MA, Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors [abstract]. J Clin Oncol 2008;26(15 Suppl):15545
   Web of Science ®Google Scholar
• Kunz PL, Kuo T, Kaiser HL, A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results [abstract]. J Clin Oncol 2008;26(15 Suppl):15502
   Web of Science ®Google Scholar
• Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008;61:661-8
   PubMed Web of Science ®Google Scholar
• Reidy-Lagunes DL, Vakiani E, Segal MF, A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 2012;118(19):4795-800
   PubMed Web of Science ®Google Scholar
• George S, Blay JY, Casali PG, Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68
   PubMed Web of Science ®Google Scholar
• Escudier B, Roigas J, Gillessen S, Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16
   PubMed Web of Science ®Google Scholar
• Raymond E, Niccoli P, Raoul J, Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). J Clin Oncol 2011;29(Suppl):4008
   Google Scholar
• Wiedmann MW, Mossner J. Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors. Clin Med Insights Oncol 2012;6:381-93
   PubMedGoogle Scholar
• Yao JC, Shah MH, Ito T, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ, Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-18
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76
   PubMed Web of Science ®Google Scholar
• Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 2007;18(6):1117
   PubMed Web of Science ®Google Scholar
• O'Reilly EM, Niedzwiecki D, Hall M, A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 2010;15(12):1310-19
   PubMed Web of Science ®Google Scholar
• Reni M, Cereda S, Milella M, Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial (NCT00967603). ASCO Meeting Abstracts 2012;4017
   Google Scholar
• Kindler HL, Friberg G, Singh DA, Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40
   PubMed Web of Science ®Google Scholar
• Ko AH, Venook AP, Bergsland EK, A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2010;66:1051-7
   PubMed Web of Science ®Google Scholar
• Spano JP, Chodkiewicz C, Maurel J, Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008;371:2101-8
   PubMed Web of Science ®Google Scholar
• Vervenne W, Bennouna J, Humblet Y, A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. 2008 ASCO Annual Meeting Proceedings J Clin Oncol 2008;26(15 Suppl):abstract 4507
   Google Scholar
• Raymond E, Dahan L, Raoul JL, Sunitinib malate for the treatment of pNETs. N Engl J Med 2011;364:501-13
   PubMed Web of Science ®Google Scholar
• Duran I, Kortmansky J, Singh D, A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95(9):1148-54
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Enzinger PC, Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24(3):401-6
   PubMed Web of Science ®Google Scholar
• Brixi-Benmansour H, Jouve JL, Mitry E, Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. Dig Liver Dis 2011;43(11):912-16
   PubMedGoogle Scholar
• Kulke MH, Kim H, Clark JW, A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004;101(5):934-9
   PubMed Web of Science ®Google Scholar